Abcam (NASDAQ:ABCM – Get Rating) had its price target hoisted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research note published on Wednesday, The Fly reports.
Separately, Panmure Gordon upgraded Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
Get Abcam alerts:Abcam Stock Performance
ABCM opened at $16.68 on Wednesday. The business has a fifty day moving average of $14.91 and a 200 day moving average of $15.54. Abcam has a 52-week low of $12.54 and a 52-week high of $24.00.
Institutional Investors Weigh In On Abcam
Several hedge funds have recently made changes to their positions in ABCM. 2Xideas AG purchased a new stake in shares of Abcam in the 4th quarter worth $16,691,000. Brown Advisory Inc. lifted its holdings in shares of Abcam by 23.7% in the 1st quarter. Brown Advisory Inc. now owns 2,914,399 shares of the company's stock worth $53,373,000 after buying an additional 558,299 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Abcam by 26.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,553,124 shares of the company's stock worth $22,458,000 after buying an additional 323,670 shares during the period. BlackRock Inc. lifted its holdings in shares of Abcam by 26.9% in the 1st quarter. BlackRock Inc. now owns 1,473,409 shares of the company's stock worth $26,948,000 after buying an additional 311,896 shares during the period. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Abcam in the 1st quarter worth $5,028,000. 11.82% of the stock is currently owned by hedge funds and other institutional investors.Abcam Company Profile
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Featured Stories
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.